- Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLCLu, S.; Fang, J.; Li, X.; Cao, L.; Zhou, J.; Guo, Q.; Liang, Z.; Cheng, Y.; Jiang, L.; Yang, N.; Han, Z.; Shi, J.; Chen, Y.; Xu, H.; Zhang, H.; Chen, G.; Ma, R.; Sun, S.; Fan, Y.; Weiguo, S.European Lung Cancer Congress (ELCC), ELECTR NETWORK, 2022-03-30 To 2022.被引 6
- Amivantamab plus chemotherapy vs chemotherapy as a first-line treatment among Asian patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer (NSCLC): PAPILLON subgroup analysisZhou, C.; Tang, K.; Liu, B.; Kim, S-W.; Kitazono, S.; Ono, A.; Thiagarajan, M.; Hung, J-Y.; Boyer, M.; Xie, J.; Bhattacharya, A.; Baig, M.; Agrawal, T.; Knoblauch, R. E.; Cho, B. C.Annual Meeting of the European-Society-for-Medical-Oncology (ESMO), SINGAPORE, 2023-12-01 To 2023-12-03.
- Tepotinib plus osimertinib for EGFR mutant (EGFRm) NSCLC with MET amplification (METamp) after first-line (1L) osimertinibTan, Daniel Shao-Weng; Kim, Tae Min; Guarneri, Valentina; Voon, Pei Jye; Lim, Boon Khaw; Wislez, Marie; Huang, Cheng; Liam, Chong Kin; Mazieres, Julien; Tho, Lye Mun; Hayashi, Hidetoshi; Nhung, Nguyen; Chia, Puey Ling; De Marinis, Filippo; Le, Xiuning; Karachaliou, Niki; Brutlach, Sabine; Adrian, Svenja; Ellers-Lenz, Barbara; Wu, Yi-LongAnnual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL, 2023-06-02 To 2023-06-06.
会议论文
Capmatinib in Chinese adults with EGFR wt, ALK rearrangement negative (ALK-RL), MET exon 14 skipping mutation (METex14), advanced NSCLC: Results from the phase II GEOMETRY-C study
4阅读
